# EDGAR Filing Document

**Accession Number:** 0001618835
**File Stem:** 0001618835-23-000005
**Filing Date:** 2023-1
**Character Count:** 9117
**Document Hash:** 2a71d107b639d3c82607c92a4546b0e0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001618835-23-000005.hdr.sgml**: 20230112

**ACCESSION NUMBER**: 0001618835-23-000005

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20230112

**ITEM INFORMATION**: Other Events

**FILED AS OF DATE**: 20230112

**DATE AS OF CHANGE**: 20230112

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Evofem Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0001618835
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 208527075
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36754
- **FILM NUMBER:** 23525694

**BUSINESS ADDRESS:**
- **STREET 1:** 12400 HIGH BLUFF DRIVE
- **STREET 2:** SUITE 600
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130
- **BUSINESS PHONE:** (858) 550-1900

**MAIL ADDRESS:**
- **STREET 1:** 12400 HIGH BLUFF DRIVE
- **STREET 2:** SUITE 600
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Neothetics, Inc.
- **DATE OF NAME CHANGE:** 20140905

?xml version="1.0" ? evfm-20230112

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): January 12, 2023**

**EVOFEM BIOSCIENCES, INC.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-36754** | **20-8527075** |
| **(State or other jurisdiction<br>of incorporation)** | **(Commission<br>File Number)** | **(IRS Employer<br>Identification No.)** |

---

**12400 High Bluff Drive, Suite 600, San Diego, CA 92130**

**(Address of principal executive offices and zip code)**

**(858) 550-1900**

**(Registrant's telephone number, including area code)**

**Not applicable.**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<u>see</u> General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, par value $0.0001 per share | EVFM | OTCQB Venture Market |

---

------

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

| | |
|:---|:---|
| **Item 08.01.** | **Other Events.** |

---

On January 12, 2023, Evofem Biosciences, Inc. (the "Company") issued a press release announcing that the telehealth company Favor (formerly called The Pill Club) is now a specialty pharmacy provider of Phexxi® (lactic acid, citric acid and potassium bitartrate). A copy of the Press Release that includes the announcement of the above is furnished herewith as Exhibit 99.1.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | <u>[Press Release](ex99120230112_evfmheyfavor.htm)</u>. |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **EVOFEM BIOSCIENCES, INC.** | **EVOFEM BIOSCIENCES, INC.** |
| Date: January 12, 2023 | By: | /s/ Justin J. File |
|  |  | Justin J. File<br>Chief Financial Officer |

---

## Exhibit 99.1

![image_0.jpg](image_0.jpg)

**Evofem's Phexxi Contraceptive Gel to be Offered by Female Telehealth Leader Favor (Formerly The Pill Club)**

*-- Phexxi is the first and only hormone-free contraceptive in the Favor product portfolio --*

SAN DIEGO, CA, January 12, 2023 —Evofem Biosciences, Inc. (OTCQB: EVFM) announced today that female telehealth leader Favor is now a specialty pharmacy provider of <u>Phexxi®</u> (lactic acid, citric acid and potassium bitartrate).

<u>Favor</u> (formerly called The Pill Club) has added Phexxi to its product portfolio and will counsel patients on this hormone-free prescription contraceptive gel alongside the more than 120 hormonal options they currently offer. Evofem expects the collaboration will begin contributing to retail channel growth in 2023. Favor's expert medical providers have prescribed contraception to more than three million patients since 2016.

"We are delighted that Favor is expanding its portfolio to offer its patients a non-hormonal contraceptive - Phexxi," said Saundra Pelletier, Chief Executive Officer of Evofem. "Phexxi appeals to a wide variety of women who seek hormone-free contraception, whether by need or by choice, offering them a safe and effective, FDA-approved contraceptive method that they control and use only when they need it."

"We are proud to offer Phexxi for women and people who menstruate seeking non-hormonal contraceptive options," said Liz Meyerdirk, Favor's Chief Executive Officer. "Hormonal contraceptives aren't for everyone; in fact, thousands of patients come to Favor every year who need a non-hormonal birth control method, and I'm thrilled that we can now deliver a trusted option right to their doorstep."

**About Favor**

Favor is a leading digital healthcare platform on a mission to empower women and people who menstruate to lead their healthiest lives. The company combines telemedicine and direct-to-consumer pharmacy with the broadest insurance coverage in the space. Since their founding in 2016,

------

Favor has evolved from a single-point solution focused on birth control delivery and reproductive healthcare to a coordinated care provider that seeks to expand access to affordable, convenient, and accessible healthcare.

**About Evofem** 

Evofem Biosciences, Inc., is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. The Company's first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at <u>phexxi.com</u> and <u>evofem.com</u>.

*Phexxi*<sup>®</sup> *is a registered trademark of Evofem Biosciences, Inc.*

**Forward-Looking Statements**

This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 including, without limitation, statements related to the timing and impact of the collaboration's contribution to retail channel growth. Various factors could cause actual results to differ materially from those discussed or implied in the forward-looking statements, including market and other conditions, and you are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements, or that could impair the value of Evofem Biosciences' assets and business, are disclosed in the Company's SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 10, 2022, its Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 filed with the SEC on January 6, 2023 and any subsequent filings. All forward-looking statements are expressly qualified in their entirety by such factors. The Company does not undertake any duty to update any forward-looking statement except as required by law.

**Contacts**

**Evofem Biosciences, Inc.**

Amy Raskopf

SVP, Investor Relations

araskopf@evofem.com / media@evofem.com<br>(917) 673-5775

**Favor**

Sarah Abboud

Director of Communications

sarah.abboud@heyfavor.com

740-579-1829

------

###

<br>